A verification study of the reduction effect of body fat

Recruitment & Eligibility

Status: Complete: follow-up complete

Sex: All

Target Recruitment: 66

Inclusion Criteria

Not provided

Exclusion Criteria

1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Subjects who currently undergoing treatment for any of the following chronic disease: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who take "Foods for Specified Health Uses," "Foods with Functional Claims," or other functional food/beverage in daily use 5. Subjects who currently taking medications (including herbal medicines) and supplements 6. Subjects who are allergic to medicines and/or the test food related products 7. Subjects who are pregnant, lactation, or planning to become pregnant 8. Subjects who suffer from COVID-19 9. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial 10. Subjects who are judged as ineligible to participate in the study by the physician

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
1. The abdominal visceral fat area at 12 weeks after consumption (12w)

Secondary Outcome Measures

Name	Time	Method
1. The abdominal visceral fat area at 8 weeks after consumption (8w) 2. The abdominal total fat area, the abdominal subcutaneous fat area, body weight, body mass index (BMI), body fat percentage, fat mass, lean body mass, muscle mass, body water, systolic blood pressure, diastolic blood pressure, and blood test {glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride (TG)} at 8w and 12w

Related Trials